Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication.
Vadhan-Raj
S
S
Department of Bio-Immunotherapy, University of Texas, Houston, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D019070:Cell Lineage; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068817:Epoetin Alfa; D016178:Granulocyte-Macrophage Colony-Stimulating Factor